PDT Partners’s Corcept Therapeutics CORT Stock Holding History

PDT Partners’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,965	Closed	-$585K	–	988
2022 Q1	$585K	Sell	25,965 -462	-2%	-$9.83K	0.05%	531
2021 Q4	$523K	Buy	26,427 +15,691	+146%	+$318K	0.04%	515
2021 Q3	$211K	Buy	+10,736	New	+$225K	0.02%	682
2020 Q1	–	Sell	-21,800	Closed	-$264K	–	686
2019 Q4	$264K	Buy	+21,800	New	+$303K	0.02%	574
2016 Q1	–	Sell	-51,700	Closed	-$257K	–	566
2015 Q4	$257K	Sell	51,700 -54,300	-51%	-$245K	0.04%	327
2015 Q3	$399K	Sell	106,000 -19,801	-16%	-$100K	0.01%	971
2015 Q2	$756K	Buy	125,801 +111,401	+774%	+$683K	0.02%	830
2015 Q1	$81K	Buy	+14,400	New	+$52.1K	﹤0.01%	1334

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDT Partners's CORT Position: Q2 2022 in Review

PDT Partners sold out of Corcept Therapeutics (CORT) in Q2 2022, closing a stake of 25,965 shares — an estimated $585K sold.

PDT Partners first reported a position in CORT in Q1 2015 and held it in 8 quarters. The position peaked at $756K in Q2 2015. 225 funds tracked by Wall St. Rank hold CORT as of Q2 2022.

PDT Partners reported no remaining Corcept Therapeutics position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 25,965 Corcept Therapeutics shares in Q2 2022, an estimated $585K.
PDT Partners first reported a position in Corcept Therapeutics in Q1 2015 and held it in 8 quarters.
PDT Partners's Corcept Therapeutics position peaked at $756K in Q2 2015.
225 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.